BERKELEY, Calif., April 9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that researchers from the Mayo Clinic will be presenting data on the use of XOMA’s high-affinity antibody to interleukin-1 beta (IL-1 beta), XOMA 052, in myeloma at the 101st Annual Meeting of the American Association of Cancer Research (AACR).
